Bruker (BRKR) Expected to Announce Quarterly Earnings on Wednesday

Bruker (NASDAQ:BRKR - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $763.83 million for the quarter. Bruker has set its FY 2025 guidance at 2.670-2.720 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Price Performance

Shares of NASDAQ:BRKR traded up $1.09 during trading on Friday, reaching $40.44. The company had a trading volume of 3,505,606 shares, compared to its average volume of 1,528,202. The firm's fifty day moving average is $42.05 and its 200 day moving average is $51.95. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market capitalization of $6.13 billion, a PE ratio of 53.21, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a twelve month low of $34.10 and a twelve month high of $79.78.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's payout ratio is currently 26.32%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Citigroup cut their target price on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Barclays decreased their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, Stifel Nicolaus cut their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and a consensus price target of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.